Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...

Severe Aplastic Anemia is a rare, life-threatening hematologic disorder in which the bone marrow fails to produce sufficient ...

Dispersing federal research funding, largely concentrated at private universities on the coasts, to the rest of the country ...

The R&D pipeline for depression therapies faced a demoralizing 2025 as five high-profile candidates, including KOR ...